Abionyx Pharma reports positive results from Phase 2a clinical trial
LAKELAND–Abionyx Pharma reported that the pilot Phase 2a clinical trial evaluating its drug candidate CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of …